The Drug-Drug Interaction Profile of Presatovir.
This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3. As expected, based on the role of CYP3A in presatovir metabolism, presatovir exposure was increased by cobicistat (122% in AUCinf ), and decreased by rifampin (40.3% in Cmax and 82.5% in AUCinf ) and efavirenz (55.7% in AUCinf ). These data support coadministration of presatovir with inhibitors of P-gp, BCRP, OATP1B1/1B3, or CYP3A, but not with moderate or strong CYP3A4 inducers. Presatovir was well-tolerated with the most common drug-related adverse events of dizziness (n = 12) and somnolence (n = 4) reported during efavirenz treatment. PMID: 29412463 [PubMed - as supplied by publisher]
Conclusions: Sensitivity of thoracentesis for solid tumors varies significantly depending on the type of tumor and is lowest in those with sarcomas, head and neck malignancies, and renal cell cancers.Respiration
Substantial variation exists among US surgeons in how likely they are to omit axillary lymph node dissection in early breast cancer despite recommendations to do so under well-defined circumstances.Medscape Medical News
Martina Cusan, Giorgia Mungo, Mara De Marco Zompit, Ilenia Segatto, Barbara Belletti, Gustavo Baldassarre
AbstractBreast cancer survivors have specific healthcare needs. As a result of their disease and treatment, they have to adapt to different physical and psychosocial late effects. Unfortunately, several studies have documented insufficiency in the survivorship healthcare system. The aim of this paper was to describe the process of development and testing of a novel Cancer Self-management Education programme (CSME programme) to improve patient-reported self-management and self-efficacy for patients with breast cancer who were at the end of primary treatment. The development of the educational programme was inspired by the P...
The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15575484.htm
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
This article is licensed under aCreative Commons Attribution-NonCommercial 3.0 Unported Licence.Fay Nicolson, Lauren E. Jamieson, Samuel Mabbott, Konstantinos Plakas, Neil C. Shand, Michael R. Detty, Duncan Graham, Karen Faulds Multiplexed imaging of three nanotags within live breast cancer tumour models through depths of 10 mm using handheld SESORRS. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Condition: Breast Cancer Intervention: Drug: T-DM1 Sponsors: Dana-Farber Cancer Institute; Susan G. Komen Breast Cancer Foundation; Gateway for Cancer Research Not yet recruiting
We describe 2 patients with local recurrence 3 and 9 years, respectively, after mastectomy with DIEAP (deep inferior epigastric artery perforator) flap breast reconstruction. Patients generally present with a palpable mass, pain, or other visible abnormalities. Various imaging techniques are helpful, always completed by biopsy to characterize the tumour. A repeated sentinel node procedure can be useful in staging. The treatment of the local recurrence needs to be determined in a multidisciplinary team consultation.Case Rep Oncol 2018;11:493 –498